Skip to content

US · PLYX · BIOTECHNOLOGY

Polaryx Therapeutics, Inc. Common Stock (PLYX) intrinsic value and stock valuation

$1.33as of 2026-11-21 · Mkt cap 111.66M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Polaryx Therapeutics, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values PLYX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PLYX’s statements →

Polaryx Therapeutics, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Paramus, NJ 07652 polaryx.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$0.00
20232025
Net income
-$-8.98M
20232025
Free cash flow
-$-3.94M
20232025
Total equity
$4.57M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$0.00$0.00$0.00
Operating income-$-7.82M-$-4.35M-$-3.78M
Net income-$-8.98M-$-30.36M-$-3.78M
EPSd-$-189.69K-$-160.32K-$-19.96K
Operating cash flow-$-3.94M-$-2.57M-$-170K
Capital expenditure$0.00$0.00$0.00
Free cash flow-$-3.94M-$-2.57M-$-170K
Total assets$5.42M$5M$2.31M
Total debt$0.00$0.00$130K
Net debt-$-5.14M-$-4.62M$130K
Total equity$4.57M$4.71M$1.28M
Cash and short-term investments$5.14M$4.62M$0.00
Income statement
202520242023
Revenue$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00
Research and development expenses$6.27M$2.81M$2.77M
Selling, general and administrative expenses$1.55M$1.54M$1.01M
Other expenses$0.00$0.00$0.00
Operating expenses$7.82M$4.35M$3.78M
Cost and expenses$7.82M$4.35M$3.78M
Interest income$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00
Ebitda-$-8.98M-$-30.36M-$-3.78M
Operating income-$-7.82M-$-4.35M-$-3.78M
Total other income/expenses, net-$-1.16M-$-26M$0.00
Income before tax-$-8.98M-$-30.36M-$-3.78M
Income tax expense$0.00$0.00$0.00
Net income-$-8.98M-$-30.36M-$-3.78M
Weighted average shares outstanding$47.3M$189.4M$189.4M
Weighted average diluted shares outstanding$47.3M$189.4M$189.4M
Balance sheet
202520242023
Cash and short-term investments$5.14M$4.62M$0.00
Net receivables$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Total current assets$5.17M$5M$2.31M
Property, plant and equipment, net$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00
Total non-current assets$250K$0.00$0.00
Total assets$5.42M$5M$2.31M
Accounts payable$470K$70K$470K
Short-term debt$0.00$0.00$130K
Deferred revenue$0.00$0.00$0.00
Total current liabilities$600K$290K$1.04M
Long-term debt$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$250K$0.00$0.00
Capital lease obligations$0.00$0.00$0.00
Total liabilities$850K$290K$1.04M
Common stock$10K$20K$0.00
Retained earnings-$-99.64M-$-90.65M-$-60.29M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity$4.57M$4.71M$1.28M
Total investments$0.00$0.00$0.00
Total debt$0.00$0.00$130K
Net debt-$-5.14M-$-4.62M$130K
Cash flow statement
202520242023
Net income-$-8.98M-$-30.36M-$-3.78M
Depreciation and amortization$0.00$0.00$0.00
Stock-based compensation$0.00$2.4M$3.24M
Change in working capital$320K-$-620K$370K
Accounts receivable$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Accounts payable$400K-$-400K-$-50K
Net cash provided by operating activities-$-3.94M-$-2.57M-$-170K
Investments in property, plant and equipment$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00
Common stock issued$4.47M$7.32M$0.00
Common stock repurchased$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$4.47M$7.19M$130K
Net change in cash$520K$4.62M-$-40K
Cash at end of period$5.14M$4.62M$0.00
Operating cash flow-$-3.94M-$-2.57M-$-170K
Capital expenditure$0.00$0.00$0.00
Free cash flow-$-3.94M-$-2.57M-$-170K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Polaryx Therapeutics, Inc. Common Stock

        Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.

        CEO
        Alex Yang
        Employees
        11
        Beta
        -9.19

        Explore

        Frequently asked questions

        What is the intrinsic value of Polaryx Therapeutics, Inc. Common Stock (PLYX)?

        InvestorsCraft does not currently publish an intrinsic value for PLYX. How the IC value is calculated.

        Is PLYX undervalued?

        InvestorsCraft does not publish an undervaluation signal for PLYX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.